trial

Prevention of Weight Gain in Early Psychoses

NCTId NCT01075295

as of 2026-07-01

Add to landscape Monitor this Ask about this

at a glance

— · Completed

Enrollment 70 (actual)

Sponsored by Centre for Addiction and Mental Health

Primary completion 2012-12

Synthesized from structured facts only — each point cited above.

Design & status

Phase

—

Status

Completed

Enrollment

70 (actual)

Study type

Interventional

Allocation

Randomized

Model

Parallel

Masking

None

Start

2010-02

Primary completion

2012-12

Eligibility

ALL · 14 Years · 45 Years

Interventions & indications

Drugs

Behavioural Intervention for the Prevention of Weight Gain TAU

Indications

Bipolar Disorder Schizophreniform Disorder Substance-Induced Psychoses Major Depressive Disorder Psychoses, Substance-Induced Schizoaffective Disorder Depressive Disorder, Major Bipolar I Disorder Psychotic Disorders Coronary Disease Schizophrenia Schizophrenia

Investigators

Rohan Ganguli, MDPrincipal Investigator

Sites

1 total

Toronto, Canada

Facts & assertions

4 sourced

Enrollment

Phase

Primary Completion Date

2012-12

Status

COMPLETED

relationships

The graph out of here

drug

Behavioural Intervention for the Prevention of Weight Gain

drug

TAU

drug

lead_sponsor

Centre for Addiction and Mental Health

company

collaborator

Canadian Institutes of Health Research (CIHR)

company

indication

Bipolar Disorder

indication

Schizophreniform Disorder

indication

Substance-Induced Psychoses

indication

investigator

Rohan Ganguli, MD

person